REG - hVIVO plc - 2018 Annual Report and Financial Statements

hVIVOAnnouncement

26/04/2019 10:00

RNS Number : 2431X
hVIVO plc
26 April 2019
 


hVIVO plc
("hVIVO" or the "Company")
 
2018 Annual Report and Financial Statements and Annual General Meeting 2019
 
 
London, UK - 26 April 2019: hVIVO plc (AIM: HVO), announces that the following documents have been sent to shareholders.
 
·      Annual Report and Financial Statements for the year ended 31 December 2018
·      Notice of Annual General Meeting ("AGM") 2019
·      Form of Proxy for the AGM
 
In accordance with AIM Rule 26, these documents are available on Company's website at, http://hvivo.com/investors/financial-reports/.
 
The AGM is scheduled to be held at 10.00am BST on Thursday 30 May 2019 on 3rd Floor, Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2AX.
 
 
For further information please contact:
 



hVIVO plc








Trevor Phillips (Executive Chairman)


+44 207 756 1300




Shelley Fraser (Finance Director & Company Secretary)
Fleur Wood (EVP, Investor Relations & Communications)
 


 




Numis Securities Limited


 +44 207 260 1000




Freddie Barnfield / Huw Jeremy (Nominated Adviser)








James Black / Michael Burke (Corporate Broking)


















FTI Consulting








Simon Conway / Victoria Foster Mitchell


+44 203 727 1000



 
 
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2700 volunteers.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACSSELSAMFUSEIL